Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma

Ricke, Jens; Schinner, Regina; Seidensticker, Max; Gasbarrini, Antonio; van Delden, Otto; Amthauer, Holger; PEYNİRCİOĞLU, BORA; Bargellini, Irene; Iezzi, Roberto; De Toni, Enrico; Malfertheiner, Peter; Pech, Maciej; Sangro, Bruno

doi:10.1016/j.jhep.2021.07.037

Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma

Ricke J., Schinner R., Seidensticker M., Gasbarrini A., van Delden O. M., Amthauer H., ...Daha Fazla

JOURNAL OF HEPATOLOGY, cilt.75, sa.6, ss.1387-1396, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 75 Sayı: 6
Basım Tarihi: 2021
Doi Numarası: 10.1016/j.jhep.2021.07.037
Dergi Adı: JOURNAL OF HEPATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
Sayfa Sayıları: ss.1387-1396
Anahtar Kelimeler: ALBI score, Hepatocellular carcinoma, Radioembolization, Selective internal radiation therapy, Sorafenib, RADIOEMBOLIZATION, DISEASE, PREVENTION, Y-90
Hacettepe Üniversitesi Adresli: Evet

Özet

Background & Aims: SORAMIC is a previously published randomised controlled trial assessing survival in patients with advanced hepatocellular carcinoma who received sorafenib with or without selective internal radiation therapy (SIRT). Based on the per-protocol (PP) population, we assessed whether the outcome of patients receiving SIRT+sorafenib vs. sorafenib alone was affected by adverse effects of SIRT on liver function.